 LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, United Kingdom , Nov. 28, 2019 CNW Telbec - Liminal BioSciences Inc. NASDAQ: LMNL TSX: LMNL Liminal BioSciences or the Company , a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorité des Marchés Financiers AMF in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019 . The AMF is the regulatory and oversight body for Québecs financial sector. 